Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911007 | 0.79 | TAAR1 (0.44) | TAAR1IDO1ALDH1A1POLBHRH3 | |
| SCHEMBL10350805 | 0.77 | TAAR1 (0.46) | TAAR1IDO1ALDH1A1ACHEPOLB | |
| SCHEMBL28337641 | 0.77 | TAAR1 (0.46) | TAAR1IDO1ALDH1A1ACHEPOLB | |
| SCHEMBL56215 | 0.74 | TAAR1 (0.41) | TAAR1MAOB | |
| SCHEMBL23886405 | 0.72 | TAAR1 (0.48) | TAAR1IDO1ALDH1A1POLBHRH3 | |
| SCHEMBL30000562 | 0.69 | TAAR1 (0.60) | TAAR1IDO1ALDH1A1ACHEDAO | |
| SCHEMBL1263547 | 0.69 | TAAR1 (0.60) | TAAR1IDO1ALDH1A1ACHEDAO | |
| SCHEMBL8096473 | 0.69 | TAAR1 (0.74) | TAAR1IDO1ACHEDAOHRH3 | |
| SCHEMBL29459538 | 0.69 | TAAR1 (0.60) | TAAR1IDO1ALDH1A1ACHEDAO | |
| SCHEMBL29596752 | 0.69 | TAAR1 (0.74) | TAAR1IDO1ACHEDAOHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922832-B1 | GLUTAMINASE INHIBITORS AND METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10414740-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180370930-A1 | GLUTAMINASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2018-12-27 | — | — | US | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9303002-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| EP-2922832-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081925-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011574-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | TAAR1 4666/4885IDO1 2093/4885ALDH1A1 553/4885 |
| US-10414740-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | TAAR1 4666/4885IDO1 2093/4885ALDH1A1 553/4885 |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | TAAR1 4692/4885IDO1 1760/4885ALDH1A1 706/4885 |
| US-20180370930-A1 | GLUTAMINASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | TAAR1 4666/4885IDO1 2093/4885ALDH1A1 553/4885 |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | TAAR1 4789/4885IDO1 2680/4885ALDH1A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.